Introduction
PsA is a heterogeneous disease including different subtypes of joint manifestations [1] . The extension of inflammation beyond the joints is another interesting feature of PsA [2] . Musculoskeletal manifestations appear to be more complex than those in other types of inflammatory arthritis, such as dactylitis, which is a frequent finding involving tendons, entheses, subcutaneous tissue, multiple joints and, possibly, the nails. In addition, anatomically anchored structures, such as the entheses, the nails and the joints, seem to be involved in the same process [3] . To date, it has not been clarified which factors lead to which subtype of joint disease other than women having more frequent peripheral arthritis, men with more spinal disease with a more severe disease course associated, and HLA-B27 being associated with more severe axial inflammation [47] .
Genetic and environmental factors may play a role in the prevalence of PsA, and the disease features may not be uniform across cultures. Therefore, epidemiological data from different genetic backgrounds are needed for a better understanding of the disease.
To be able to understand the nature of PsA in our population, a multicentre registry was built in Turkey in 2014. The objective of this registry was to see the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. To make sure that the registry represents the whole country, a multicentre study was conducted. Here, the demographics of our registry are given in comparison with the other well-established registries.
Methods

General information
The psoriatic arthritis registry of Turkey (PsART) was established in 2014 and includes 32 rheumatology centres across Turkey. PsART data are collected using a Webbased system (www.favor.org). Individual centres have direct access to their own local data, whereas the principal investigators (U.K. and S.Z.A.) have access to the centralized data set. Data are collected following the recommendations of a survey led by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis at the annual meeting in 2007 [8] . Ethical approval was obtained from the Hacettepe University Ethics Board, and all patients gave informed consent prior to data collection. The data that are presented in this article represent one of the main outcomes of the PsART registry.
Collection of demographic data
Sex, date of birth, education level, smoking status, weight, height and calculated BMI were collected.
Data for psoriasis
Psoriasis onset date (month/year), type of psoriasis (plaque, pustular, inverse, erythrodermic), initial skin involvement site, family history of psoriasis and PsA were collected. Nail involvement was recorded as presence or absence as well as the type of nail involvement (pitting and/or onycholysis).
Data for PsA
Consecutive subjects with a diagnosis of PsA according to the rheumatologists were recruited to the registry. Fulfilling the ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria was not mandatory but this was also analysed [9] . The data regarding joint involvement included the date of initial diagnosis and the PsA pattern. The presence of axial involvement was based on the physician's assessment, according to the presence of inflammatory lower back pain. In the absence of a validated definition of inflammatory lower back pain in PsA, all items of the Calin et al. [10] , Assessment of SpondyloArthritis international Society [11] and Berlin Criteria [12] for inflammatory lower back pain were included.
Outcome measures for PsA
Patient-reported outcomes
Patient global assessment (GA), fatigue and pain were assessed with a visual analog scale (VAS) from 0 to 100 mm. The duration of morning stiffness was assessed in minutes. Function and disability were assessed with HAQ [13] . BASDAI [14] and BASFI [15] were used to assess disease activity and function. Skin involvement was assessed by the psoriasis symptom inventory (PSI). The PSI is a relatively new patient-reported outcome measure consisting of eight items assessing skin symptoms and response options on a five-point Likert-type rating scale and includes itching, redness, scaling, burning, stinging, cracking, flaking and pain [16] . The PSI was not included in the registry from the beginning and was added subsequently. For that reason, the PSI data were available for only a subgroup of patients.
Physician-reported outcomes
Physician GA of disease activity (VAS 0100 mm), swollen (66 joint) joint count and tender (68 joint) joint count were assessed. The joints with damage were recorded according to clinicians' physical examination and classified according to the presence of ankylosis, subluxation and limitations in the range of motion, telescopic finger and arthritis mutilans. Presence (current or ever) or absence of dactylitis and enthesis were also recorded. The Leeds Enthesis Index (LEI) was used to assess for enthesitis at the following three sites, bilaterally: Achilles tendons, humeral lateral epicondyle and medial femoral condyle [17] . The body surface area percentage was used for skin involvement. Of note, the severity of the skin psoriasis assessment was not mandatory and was therefore recorded only by investigators who were familiar with the scoring.
Laboratory tests
The RF status (positive/negative), ANA and ACPA were collected whenever available.
Treatment protocols
Data on the usage of conventional synthetic DMARDs (csDMARDs; such as MTX, SSZ, HCQ, LEF and CSA), glucocorticoids and anti-TNF agents (adalimumab, etanercept, infliximab and golimumab) were recorded. For each drug, the start dates, initial dosage, withdrawal date, the reason for withdrawal, last dosage as reported by patient report and/or medical records as well as switching were collected.
Dealing with inappropriate and missing data
For cross-sectional analysis, all data were visually screened by three investigators (O.B., U.K. and S.Z.A.), and 450 items that were found inappropriate were sent to the centres with queries. After verification, the numbers (percentages) of missing data were as follows: nail involvement 1 (0.1%), family history 3 (0.3%), PsA joint pattern 8 (0.7%), treatment history 11 (1.0%), smoking 12 (1.1%), fulfilling the CASPAR criteria 16 (1.5%), swollen joint count 38 (3.5%), tender joint count 38 (3.5%), dactylitis 46 (4.3%), inflammatory lower back pain 58 (5.4%), enthesitis 69 (6.4%), LEI 78 (7.2%), morning stiffness 129 (11.9%), educational level 160 (14.8%), initial affected psoriasis area 208 (19.2%), joint count with damage 319 (29.5%), pain VAS 325 (30.1%), fatigue VAS 331 (30.6%), patient GA VAS 348 (32.2%), psoriasis type 371 (34.3%), HAQ 382 (35.3%), physician GA VAS 402 (37.2%), BASDAI 498 (46.1%), BASFI 508 (47.0%), PSI 672 (62.0%), body surface area 675 (62.4%), and PSI or body surface area 456 (42.2%).
Statistical analysis
This was the first cross-sectional analysis at baseline 10 months after launching the PsART. Descriptive statistics were performed with the frequencies and percentages for categorical variables, mean and S.D., or median and range. All data were initially analysed for the whole group, followed by division according to the sex, to determine the differences between women and men. Categorical variables were compared using a 2 test. Continuous variables were compared by student's t test or Mann-Whitney U test, depending on the distribution of the data. The software used was SPSS 21.0 (Hacettepe University).
Results
General information
Between . A minority of patients had only DIP involvement (n = 6, 5.8%) or arthritis mutilans (n = 5, 0.5%). In the current assessment of swollen joints, PIPs (n = 148; 36.4%) were the most commonly affected joints, followed by knees (n = 114; 28.0%), MCPs (n = 94; 23.1%), ankles (n = 92; 22.6%) and wrists (n = 79; 19.4%).
Outcome measures
The mean (S.D.) values for patient-and physician-reported outcome measurements are listed in anti-TNF plus two csDMARDs 31 (3.3%). A previous switch on anti-TNF drugs was present in 104 of 323 (32.2%) patients.
Differences between sexes
Women were significantly older than men at the time of the study as well as at the time of diagnosis ( In terms of patient-related outcomes, women had more severe fatigue and their functional assessment was worse according to the HAQ scores. Despite having more fatigue, the women's perception of pain, GA and PSI for skin involvement were similar to those of men.
For physician-reported outcomes, all assessments were similar in both sexes. For MDA components, women had less skin involvement (according to body surface area 43) and pain, but men had better function according to HAQ 40.5 (Tables 2 and 3 ). Although the difference in MDA did not reach significance between women and men (38.6 vs 48.4% consecutively, P = 0.13), according to DAS28, women had higher disease activity [mean (S.D.) DAS28 for women 3.61 (1.28) and for men 3.21 (1.38); P < 0.001]. Also, the rate of remission was lower in women [n (%) of high, moderate and low disease activity and remission by DAS28: women 61 (13.6), 102 (22. 
Discussion
The PsART is a multicentre, large, national cohort, for which we present the baseline demographic data, clinical features and treatment choices. Our registry had some similarities with the previously published registries, supporting its external validity.
Classically, five dominant disease patterns were defined in PsA in 1973 [18] . However, these patterns are not always clear and frequently overlap. In our patients, only one disease pattern was found in almost 60% of patients, with other patients having various types of combinations. Within joint patterns, we found that women had more frequent peripheral disease, whereas axial disease was more common among men [6, 7] , similar to the previous literature. Unlike the previous studies that have shown that polyarticular involvement was predominant in women compared with an oligoarticular pattern in men, we did not observe the pattern differences for oligo-and polyarthritis between sexes [19, 20] . In 2002, the treatment choices of 1863 PsA patients from Germany were published, which were comparable to our registry, with the exception of biological treatments being higher in our registry, possibly because of the year of data collection and availability of the medications (29.6% were on biologics in PsART vs 2.1% in the German database) [21] . When we compared the treatment choices other than biologics, MTX (65.6 vs 65.9%) and low-dose glucocorticoids (25.9 vs 26.6%) were used at a similar rate, whereas SSZ (20.5 vs 12.0%) and HCQ (7.8 vs 2.7%) as well as a combination of more than one DMARD (22.6 vs 12.7%) were more frequently used in our registry. Fewer patients were not on any DMARDs in PsART (9.2 vs 16.1%). Our treatment choices were also compliant with the international recommendations. Both Group for Research and Assessment of Psoriasis and Psoriatic Arthritis [22] and EULAR [23] recommend synthetic DMARDs, especially MTX, as a first-line treatment option. In PsART, MTX was the most commonly used DMARD. Currently, two-thirds of PsA patients were still using MTX. Although HCQ is not part of the recommendations, a population-based cohort from the UK showed that 250 of 4155 (6.0%) PsA patients who were on DMARD had been prescribed HCQ [24] . Likewise, in PsART, currently 7.8% of patients had ever used HCQ, and mostly in combination with MTX. This result shows that although not a part of the recommendations, Again, according to EULAR recommendations, in patients who fail to respond adequately to one anti-TNF agent, switching to another anti-TNF agent should be considered, which was almost one-third of patients in the PsART. Despite the majority of patients being on monoor combined DMARD therapies and/or anti-TNF treatments, the cross-sectional analysis demonstrated that almost half of PsA patients had active disease status according to various outcome measures, such as pain and patient and physician GA. Our results illustrate the unmet need in PsA, and new treatment options could potentially overcome this need [25] . There were also some interesting differences between our registry and the previously published PsA cohorts. Gender was one of those differences. Almost two-thirds of PsART patients were women in our registry, despite the fact that psoriasis is equally prevalent in both sexes in our population, as shown in the Turkey psoriasis study [26] . PsA is slightly less frequent in women in some other cohorts; for instance, in CASPAR, GRACE and Toronto PsA cohorts, 43.2, 48.0 and 43.5% of patients, respectively, were women [9, 27, 28] . However, a population-based survey in Sweden found that PsA was slightly more frequent in women in all age groups [29] . As patients were consecutively recruited to our registry, a selection bias is not likely. Another reason would be the more frequent follow-up requirements of the women compared with men. A cross-sectional survey among 5604 patients with psoriasis and PsA in USA showed that female patients were 1.47 times more likely to seek care [30] . Our data showed that despite having similar objective disease activity parameters, as determined by the physician, women had more fatigue and their function loss was more significant. Also, women had higher DAS28 values as well as lower remission and low disease activity rates compared with men, which may indicate a higher unmet need in women. If women are more frequently seeking medical care, this could explain why women are more frequently recruited in a certain time frame. Supporting this, the inception cohort of newly diagnosed patients included fewer women then the whole group (64.7 vs 55.6%).
There are certain limitations of our cohort. Data were obtained from 32 centres, and heterogeneity of data may be considered a challenge in this kind of multicentre cohort. It is difficult to achieve a sufficient number of patients to be able to analyse all features of the disease in one centre. Additionally, if a high number of participants is obtained from only one centre, that has a risk of data coming only from a specialized clinic, therefore not being representative of routine practice. Missing data are another concern. Most of the demographic data, clinical features and treatment choices were missed in < 5% of patients; however, missing data for the some of the outcome measures could be as high as 30%. The definition of disease patterns was according to the clinician. Axial disease was defined based upon the presence of inflammatory low back pain, which could have led us to miss patients who had subclinical disease, viewed as having significant sacroiliitis on X-ray and being negative for back pain. The lack of routine radiographic data collection in the whole group may have led to the misclassification of patients. However, asking for routine X-rays for patients with no clinical findings would be unethical and would not necessarily influence clinical decisions even in the face of positive findings.
There were also some strengths of the cohort. This is truly representative all the whole country, as almost all regions of Turkey contributed to the registry. The centres that participated in the trial are general rheumatology clinics without being specialized in PsA and are therefore more likely to represent general rheumatology practice. The number of patients recruited is very high, allowing a more accurate identification of disease characteristics. New diagnosis of PsA was present in almost 8% of our cohort, and a diagnosis of PsA for <1 year was present in 25%. Follow-up of those patients may provide additional information about the disease course. PSI has been used for the first time in a real-life setting with a large number of patients.
In conclusion, the PsART is a newly established national, multicentre PsA registry in Turkey. The baseline characteristics of this cohort are presented in this study. Female predominance is the major demographic difference from other cohorts. Clinical features were comparable to the other cohorts. Unfortunately, almost half of the patients had an active disease level, according to various outcome measures. Although 30% of patients currently use anti-TNF drugs, there is an unmet need because of an active disease state in a large number of patients. In future, follow-up of newly diagnosed PsA patients may bring additional insights about the disease course of PsA.
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